Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quadrivalent recombinant influenza vaccine with different H3 antigens in adults
NCT04451954Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jul 2020
- Primary completion
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of Quadrivalent recombinant influenza vaccine in influenza (7 arms), sponsored by Sanofi. Primary endpoints: Immediate Adverse Events at 30 minutes, Solicited Injection Site or Systemic Reactions at 7 days and 11 more. Started Jul 2020; status: completed.
02
Drugs
Quadrivalent recombinant influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04451954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04451954.